iShares International Treasury Bond ETF (IGOV) Is At $50.67 Formed Wedge; 7 Analysts Are Bullish Sangamo Therapeutics, Inc. (SGMO) Last Week

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 26 analyst reports since August 8, 2015 according to SRatingsIntel. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Buy” rating given on Thursday, September 3 by JP Morgan. The firm has “Hold” rating given on Wednesday, November 15 by Wedbush. The rating was upgraded by PiperJaffray on Wednesday, November 15 to “Overweight”. On Thursday, February 22 the stock rating was maintained by Jefferies with “Buy”. Piper Jaffray maintained it with “Buy” rating and $32.0 target in Thursday, February 22 report. The company was maintained on Wednesday, September 2 by Wedbush. The company was maintained on Tuesday, March 13 by Wedbush. On Friday, October 23 the stock rating was reinitiated by Jefferies with “Buy”. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Sell” rating by Zacks on Tuesday, September 8. JP Morgan maintained it with “Overweight” rating and $22 target in Saturday, August 8 report. See Sangamo Therapeutics, Inc. (NASDAQ:SGMO) latest ratings:

13/03/2018 Broker: Wedbush Rating: Hold New Target: $8.0 Maintain
22/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $32.0 Maintain
22/02/2018 Broker: Jefferies Rating: Buy New Target: $33.0 Maintain
22/02/2018 Broker: Wells Fargo Rating: Buy Maintain
03/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $25.0 Maintain
22/11/2017 Broker: Barclays Capital Rating: Overweight New Target: $20 Initiates Coverage On
15/11/2017 Broker: Wedbush Rating: Hold New Target: $6.0 Maintain
13/11/2017 Broker: Cowen & Co Rating: Buy
15/11/2017 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Upgrade

iShares International Treasury Bond ETF (IGOV) formed wedge up with $53.71 target or 6.00% above today’s $50.67 share price. iShares International Treasury Bond ETF (IGOV) has $1.03B valuation. The ETF decreased 0.76% or $0.39 during the last trading session, reaching $50.67. About 99,862 shares traded. iShares International Treasury Bond ETF (NASDAQ:IGOV) has risen 12.59% since April 24, 2017 and is uptrending. It has outperformed by 1.04% the S&P500.

Since January 2, 2018, it had 0 insider purchases, and 15 insider sales for $2.56 million activity. 2,278 shares valued at $41,684 were sold by Herberts Curt A. III on Monday, April 2. Shares for $127,812 were sold by Yi Kathy. 5,000 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares with value of $92,436 were sold by Conner Edward R.. $132,758 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was sold by Mento Steven J. $235,080 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was sold by Ramasastry Saira.

The stock decreased 4.72% or $0.9 during the last trading session, reaching $18.15. About 2.07M shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 352.38% since April 24, 2017 and is uptrending. It has outperformed by 340.83% the S&P500.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.57 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart